Morgan Stanley analyst Michael Ulz raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $122 from $109 and keeps an Overweight rating on the shares after the company hosted a commercial readiness event for setmelanotide in treating hypothalamic obesity. Key opinion leaders are “excited” for approval of setmelanotide due to high unmet need and the “impressive data,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals: Buy Rating Backed by FDA Priority Review and Positive Phase 3 Results
- Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide
- Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study
- Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment
- 3 Best Stocks to Buy Now, 8/8/2025, According to Top Analysts